Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells

Prior treatment

• The participant has previously received any treatment for acute myeloid leukemia (AML), except for hydroxyurea.
• Currently participating in another clinical study or planning to initiate treatment in this study within less than 4 weeks after the completion of therapy in a prior clinical study.

Other illness

• Uncontrolled active infections (including bacterial, fungal, or viral infections) that are clinically significant and refractory to medical therapy.
• Patients who have other malignancies that require treatment.
• A history of allergy to the study drugs.
• Human immunodeficiency virus (HIV) infection or syphilis infection.
• Active hepatitis that remains uncontrolled despite active antiviral therapy (positive for hepatitis B virus deoxyribonucleic acid \[HBV DNA\] or hepatitis C virus ribonucleic acid \[HCV RNA\]).
• Patients with persistent positivity for Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 (excluding those who have transitioned from positive to negative).
• Conditions that the investigator considers may increase the risk to participants or interfere with the study results.
• Other conditions that the investigator deems the participant unsuitable for enrollment in this study.

Age

• Age \<18 years or ≥75 years.

Other

• A definitive diagnosis of Acute Promyelocytic Leukemia (APL).
• Female participants who are pregnant or breastfeeding.

• Newly diagnosed acute myeloid leukemia (AML) patients Ineligible or unwilling to receive intensive chemotherapy .①Patients deemed ineligible for intensive chemotherapy must meet the following criteria: Age 18 to 74 years with at least one of the following comorbidities; Eastern Cooperative Oncology Group (ECOG) performance status ≥3; Cardiac history requiring treatment for congestive heart failure; Left ventricular ejection fraction ≤50%; Chronic stable angina; Diffusing capacity of the lungs for carbon monoxide (DLCO) ≤65% or forced expiratory volume in 1 second (FEV1) ≤65%; Creatinine clearance ≥30 mL/min to \<45 mL/min (Cockcroft-Gault formula); Moderate hepatic impairment: total bilirubin \>1.5 to ≤3.0 × upper limit of normal (ULN); ②Other investigator-assessed comorbidities that preclude safe administration of intensive chemotherapy.
• Hepatic function must meet the following criteria: Aspartate aminotransferase (AST) ≤3.0 × upper limit of normal (ULN); Alanine aminotransferase (ALT) ≤3.0 × ULN; Total bilirubin ≤3.0 × ULN. (unless deemed attributable to leukemic organ involvement)
• Renal function must meet the following criterion: Creatinine clearance ≥30 mL/min calculated using the Cockcroft-Gault formula.
• No history of drug allergies within the protocol.
• Participants with plans for pregnancy must agree to use contraception before enrollment in the study and for six months after the study ends. If a participant becomes pregnant or suspects pregnancy, she must immediately notify the investigator.
• The participant understands and signs the informed consent form.